An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemia
Walter Fiedler(Universität Hamburg), Hubert Serve(Goethe University Frankfurt), Wolfgang E. Berdel(University Hospital Münster), Ute Zirrgiebel(Johannes Gutenberg University Mainz), Michael Heuser(Martin Luther University Halle-Wittenberg), Barbara Collins(University of Ottawa), Juliane M. Jürgensmeier(AstraZeneca (United Kingdom)), Rolf M. Mesters(University Hospital Münster), T. A. Puchalski(AstraZeneca (United States)), Jane Robertson(Cancer Research UK), Gerhard Ehninger(University Hospital Carl Gustav Carus)
Cited by 42
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k